ROCKVILLE, Md., Sept. 11, 2014 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing
novel anti-infective biologic and drug candidates targeting
specific pathogens that cause serious infections and
diseases, announced today that it will host a an
investor conference call on Friday,
September 12, 2014, at 9:15 a.m.
EDT. The conference call will highlight
TrimestaTM, the Company's oral product candidate for the
treatment of relapsing-remitting multiple sclerosis (MS),
immediately following the oral presentation at 8:39 a.m. EDT by lead academic investigator,
Rhonda Voskuhl, M.D., at the 2014
Joint Americas and European Committees for Treatment and Research
in Multiple Sclerosis Meeting (ACTRIMS-ECTRIMS) in Boston.
Interested parties should call 1-877-870-4263 (U.S. toll free),
1-855-669-9657 (Canada toll free),
or +1 412-317-0790 (International), fifteen minutes before the
start of the call to register. Registered callers on the toll free
line may ask to be placed in the queue for the Question &
Answer Session. The call will also be webcast over the Internet at
http://www.videonewswire.com/event.asp?id=100450. If you are unable
to participate during the live conference call, the webcast will be
available for replay at the same URL,
http://www.videonewswire.com/event.asp?id=100450, for 60 days after
the call.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology
company focused on the development of novel anti-infective biologic
and drug candidates targeting specific pathogens that cause serious
infections and diseases. The Company is developing an oral biologic
to protect the gastrointestinal microflora from the effects of IV
antibiotics for the prevention of Clostridium difficile (C.
difficile) infection, an oral treatment to reduce the impact of
methane producing organisms on constipation-predominant irritable
bowel syndrome (C-IBS), a series of monoclonal antibodies for the
treatment of Pertussis and Acinetobacter infections, and a
biologic targeted at the prevention and treatment of a root cause
of a subset of IBS. In addition, the Company is developing an oral
estriol drug for the treatment of relapsing-remitting multiple
sclerosis (MS) and cognitive dysfunction in MS. For more
information, please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
Logo -
http://photos.prnewswire.com/prnh/20130522/MM19465LOGO
SOURCE Synthetic Biologics, Inc.